113 related articles for article (PubMed ID: 19396793)
1. Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III.
Montero JA; Fernandez MI; Gomez-Ulla F; Ruiz-Moreno JM
Eur J Ophthalmol; 2009; 19(3):448-51. PubMed ID: 19396793
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
Konstantinidis L; Mameletzi E; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1165-71. PubMed ID: 19404661
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
Retina; 2007; 27(4):451-7. PubMed ID: 17420697
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
Saito M; Shiragami C; Shiraga F; Kano M; Iida T
Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
[TBL] [Abstract][Full Text] [Related]
6. Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation.
Viola F; Mapelli C; Villani E; Tresca Carducci F; Vezzola D; Ratiglia R
Eye (Lond); 2010 Aug; 24(8):1344-51. PubMed ID: 20339389
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation.
Joeres S; Heussen FM; Treziak T; Bopp S; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1597-602. PubMed ID: 17437123
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
[TBL] [Abstract][Full Text] [Related]
10. Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation.
Lo Giudice G; Gismondi M; De Belvis V; Cian R; Tavolato M; Galan A
Retina; 2009; 29(7):949-55. PubMed ID: 19584653
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation.
Costagliola C; Romano MR; dell'Omo R; Cipollone U; Polisena P
Am J Ophthalmol; 2007 Sep; 144(3):449-51. PubMed ID: 17765426
[TBL] [Abstract][Full Text] [Related]
12. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Shiragami C; Shiraga F; Nagayama D; Iida T
Am J Ophthalmol; 2008 Dec; 146(6):935-41.e1. PubMed ID: 18723139
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab for retinal angiomatous proliferation.
Rouvas AA; Papakostas TD; Ladas ID
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1719-20. PubMed ID: 19669654
[No Abstract] [Full Text] [Related]
14. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
15. [Anti-VEGF treatment for retinal angiomatous proliferation].
Wolf A; Kook D; Kreutzer T; Gandorfer A; Haritoglou C; Kampik A; Ulbig M
Ophthalmologe; 2008 Sep; 105(9):845-51. PubMed ID: 18607601
[TBL] [Abstract][Full Text] [Related]
16. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
17. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
